GeNeuro SA (GNRRF)
| Previous close | 4.5500 |
| Open | 4.5500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.5500 - 4.5500 |
| 52-week range | 3.1400 - 4.5500 |
| Volume | |
| Avg. volume | 247 |
| Market cap | 57.888M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4730 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
GeNeuro Announces Successful €7.7 Million Private Placement
GENEVA, May 12, 2022--Regulatory News: NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO
- Business Wire
GeNeuro Is Granted Authorization by the Swiss Health Authority (swissmedic) to Initiate a Phase II Study Evaluating Temelimab in Patients With Severe Neuropsychiatric Post‑COVID Syndromes
GENEVA, May 11, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announces today it has received the authorization by the Swiss Health Authority (Swissmedic) to initiate a Phase II study evaluating temelimab in patients with
- Business Wire
GeNeuro: Availability of Documents and Information for the Annual Shareholders’ Meeting of May 31, 2022
GENEVA, May 10, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), informs its shareholders that the 2022 Annual General Meeting will be held on Tuesday May 31, 2022 at 9.30am at its head office, 3, chemin du Pré-Fleuri, 1228 Plan-
